Finding Cancer Statistics » Cancer Stat Fact Sheets »Cancer of the Liver and Intrahepatic Bile Duct

It is estimated that 21,370 men and women (15,190 men and 6,180 women) will be diagnosed with and 18,410 men and women will die of cancer of the liver and intrahepatic bile duct in 2008¹X Close
Table I-1 (http://seer.cancer.gov/csr/ 1975_2005/results_single/ sect_01_table.01.pdf).

The following information is based on NCI’s SEER Cancer Statistics Review²X Close
Liver and Intrahepatic Bile Duct Section (http://seer.cancer.gov/csr/ 1975_2005/results_merged/ sect_14_liver_bile.pdf)
.

Incidence & Mortality

SEER Incidence

From 2001-2005, the median age at diagnosis for cancer of the liver and intrahepatic bile duct was 65 years of age³X Close
Table I-11 (http://seer.cancer.gov/csr/ 1975_2005/results_single/ sect_01_table.11_2pgs.pdf). Approximately 1.1% were diagnosed under age 20; 1.1% between 20 and 34; 3.9% between 35 and 44; 20.0% between 45 and 54; 23.2% between 55 and 64; 24.2% between 65 and 74; 20.3% between 75 and 84; and 6.2% 85+ years of age.

The age-adjusted incidence rate was 6.4 per 100,000 men and women per year. These rates are based on cases diagnosed in 2001-2005 from 17 SEER geographic areas.

US Mortality

From 2001-2005, the median age at death for cancer of the liver and intrahepatic bile duct was 70 years of age⁴X Close
Table I-13 (http://seer.cancer.gov/csr/ 1975_2005/results_single/ sect_01_table.13_2pgs.pdf). Approximately 0.4% died under age 20; 0.7% between 20 and 34; 2.7% between 35 and 44; 14.9% between 45 and 54; 19.4% between 55 and 64; 24.6% between 65 and 74; 26.6% between 75 and 84; and 10.8% 85+ years of age.

The age-adjusted death rate was 5.0 per 100,000 men and women per year. These rates are based on patients who died in 2001-2005 in the US.

Trends in Rates

Trends in rates can be described in many ways. Information for trends over a fixed period of time, for example 1995-2005, can be evaluated by the annual percentage change (APC)X Close
The average annual percent change over several years. The APC is used to measure trends or the change in rates over time. For information on how this is calculated, go to Trend Algortihms in the SEER*Stat Help system. The calculation involves fitting a straight line to the natural logarithm of the data when it is displayed by calendar year. (See Fast Stats for trends over fixed time intervals). If there is a negative sign before the number, the trend is a decrease; otherwise it is an increase. If there is an asterisk after the APC then the trend was significant, that is, one believes that it is beyond chance, i.e. 95% sure, that the increase or decrease is real over the period 1995-2005. If the trend is not significant, the trend is usually reported as stable or level. Joinpoint analysesX Close
A statistical model for characterizing cancer trends which uses statistical criteria to determine how many times and when the trends in incidence or mortality rates have changed. The results of joinpoint are given as calendar year ranges, and the annual percent change (APC) in the rates over each period can be used over a long period of time to evaluate when changes in the trend have occurred along with the APC which shows how much the trend has changed between each of the joinpoints.

Survival & Stage

Survival ratesX Close
Survival examines how long after diagnosis people live. Cancer survival is measured in a number of different ways depending on the intended purpose. Several examples of survival statistics are listed below. can be calculated by different methods for different purposes. The survival rates presented here are based on the relative survival rateX Close
A measure of net survival that is calculated by comparing observed (overall) survival with expected survival from a comparable set of people that do not have cancer to measure the excess mortality that is associated with a cancer diagnosis., which measures the survival of the cancer patients in comparison to the general population to estimate the effect of cancer. The overall 5-year relative survival rate for 1996-2004 from 17 SEER geographic areas was 11.7%. Five-year relative survival rates by race and sex were: 11.0% for white men; 12.3% for white women; 7.9% for black men; 7.7% for black women.

The stage distributionX Close
Stage provides a measure of disease progression, detailing the degree to which the cancer has advanced. Two methods commonly used to determine stage are AJCC and SEER historic. The AJCC method (see Collaborative Staging Method) is more commonly used in the clinical settings, while SEER has standardized and simplified staging to ensure consistent definitions over time. based on historic stage shows that 35% of liver and intrahepatic bile duct cancer cases are diagnosed while the cancer is still confined to the primary site (localized stage); 25% are diagnosed after the cancer has spread to regional lymphnodes or directly beyond the primary site; 20% are diagnosed after the cancer has already metastasized (distant stage) and for the remaining 20% the staging information was unknown. The corresponding 5-year relative survival rates were: 23.8% for localized; 7.7% for regional; 2.9% for distant; and 4.9% for unstaged. (See Fast Stats for more detailed statistics)

Lifetime Risk

Based on rates from 2003-2005, 0.69% of men and women born today will be diagnosed with cancer of the liver and intrahepatic bile duct at some time during their lifetime. This number can also be expressed as 1 in 145 men and women will be diagnosed with cancer of the liver and intrahepatic bile duct during their lifetime. These statistics are called the lifetime riskX Close
The probability of developing cancer in the course of one's lifespan. Lifetime risk may also be discussed in terms of the probability of developing or of dying from cancer. Based on cancer rates from 2003 to 2005, it was estimated that men had about a 44 percent chance of developing cancer in their lifetimes, while women had about a 37 percent chance. of developing cancer. Sometimes it is more useful to look at the probability of developingX Close
The chance that a person will develop cancer in his/her lifetime. cancer of the liver and intrahepatic bile duct between two age groups. For example, 0.50% of men will develop cancer of the liver and intrahepatic bile duct between their 50th and 70th birthdays compared to 0.15% for women. (See Fast Stats for more detailed statistics, and Probability of Developing and Dying of Cancer for methodology)

Prevalence

On January 1, 2005, in the United States there were approximately 21,642 men and women alive who had a history of cancer of the liver and intrahepatic bile duct -- 14,098 men and 7,544 women. This includes any person alive on January 1, 2005 who had been diagnosed with cancer of the liver and intrahepatic bile duct at any point prior to January 1, 2005 and includes persons with active disease and those who are cured of their disease. PrevalenceX Close
The number of people who have received a diagnosis of cancer during a defined time period, and who are alive on the last day of that period. Most prevalence data in SEER is for limited duration because information on cases diagnosed before 1973 is not generally available. can also be expressed as a percentage and it can also be calculated for a specific amount of time prior to January 1, 2005 such as diagnosed within 5 years of January 1, 2005. (See Fast Stats for more detailed statistics, and Overview of Prevalence Statistics for methodology)

References

All statistics in this report are based on SEER incidence and NCHS mortality statistics. Most can be found within:

Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.